Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-4324 · 2 trials · 2 indications
M-value is measured as the glucose infusion rate at steady state
| Arm | Type | Description |
|---|---|---|
| ALN-4324 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4324. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Part A: ALN-4324 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4324. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Part B: ALN-4324 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-4324 |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Name | Type | Description |
|---|---|---|
| ALN-4324 | DRUG | ALN-4324 will be administered subcutaneously (SC). |
| Placebo | DRUG | Placebo will be administered SC. |
Inclusion Criteria: * Is an adult patient with a confirmed diagnosis of T2DM * Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2 * Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5% * Is on a stable dose of metformin Exclusion Criteria: * Has any clinically significant concomitant disease,...